Health Economics Department, Weber Economía y Salud, C/Moreto 17, 5D, 28014, Madrid, Spain.
Department of Quantitative Methods in Economics and Management, University of Las Palmas de Gran Canaria, Las Palmas, Spain.
Clin Transl Oncol. 2022 Jun;24(6):968-980. doi: 10.1007/s12094-021-02757-9. Epub 2022 Jan 8.
CAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer. However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders. The experts identified three great challenges for implementing advanced therapies in Spain: therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.
嵌合抗原受体 T 细胞（CAR-T）疗法代表了在某些类型血液系统癌症的预后和治疗方面的治疗革命。然而，它们在医疗保健、监管和财务领域也带来了新的挑战。RET-A 项目的目的是对西班牙国家卫生系统中嵌合抗原受体 T 细胞疗法的管理进行战略思考，就有助于更好地应对这些细胞疗法在现在和未来带来的新情况的建议达成一致。该智库涉及 40 名关键代理和意见领袖。专家们确定了在西班牙实施先进疗法的三大挑战：个体化治疗，采用多学科方法；通过减少官僚主义来加快准入时间；增加 NHS 中有资格管理 CAR-T 疗法的中心数量。专家们就指定合格中心的理想标准达成了一致。他们还就综合的 CAR-T 护理途径达成了一致，其中包括每个过程部分中理想涉及的时间和角色。
